Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: A cancer and leukemia group B study

Journal of Clinical Oncology

Volumn 14, Issue 9, 1996, Pages 2486-2494

  Bernstein, S H ^a   Brunetto, V L ^a   Davey, F R ^a   Wurster Hill, D ^a   Mayer, R J ^a   Stone, R M ^a   Schiffer, C A ^a   Bloomfield, C D ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYTARABINE; DAUNORUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CYTOPENIA; FEMALE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS;

EID: 0029737359     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.9.2486     Document Type: Article

References (38)

1. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982
2. Bennett JM, Catovsky D, Daniel MT, et al: Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103:626-629, 1985
3. Fenaux P, Morel P, Rose C, et al: Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 77:497-501, 1991
4. Mertelsmann R, Thaler HT, To L, et al: Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 56:773-781, 1980
5. Armitage JO, Dick FR, Needleman SW, et al: Effect of chemotherapy for the dysmyelopoietic syndrome. Cancer Treat Rep 65:601-605, 1981
6. De Witte T, Muus P, De Pauw B, et al: Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer 66:831-837, 1990
7. Aul C, Schneider W: The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer 64:1812-1818, 1989
8. Tricot G, Boogaerts MA: The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol 63:477-483, 1986
9. Döhner H, Arthur DC, Ball ED, et al: Trisomy 13: A new recurring chromosome abnormality in acute leukemia. Blood 76:1614-1621, 1990
10. Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990
11. Mitelman F: Guidelines for Cancer Cytogenetics. Supplement to an International System for Human Cytogenetic Nomenclature. Basel, Switzerland, S. Karger, 1991
12. First International Workshop on Chromosomes in Leukemia: General report on the first international workshop on chromosomes in leukemia. Int J Cancer 21:307-308, 1978
13. Pierre RV, Catovsky D, Mufti GJ, et al: Clinical-cytogenetic correlations in myelodysplasia (preleukemia). Cancer Genet Cytogenet 40:149-161, 1989
14. Mayer RJ, Schiffer CA, Peterson BA, et al: Intensive post remission therapy in adults with non-lymphocytic leukemia with ara-C by continuous infusion or bolus administration: Preliminary results of a CALGB phase I study. Semin Oncol 12:84-90, 1985
15. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896-903, 1994
16. Paciucci PA, Holland JF, Gottlieb RB, et al: Sequential mitoxantrone, daunorubicin and Ara-C for patients with newly diagnosed AML. Proc Am Soc Clin Oncol 8:207, 1989 (abstr 807)
17. Schiffer CA, Davis RB, Schulman P, et al: Intensive post remission therapy of acute myeloid leukemia (AML) with cytoxan/ etoposide (CY/VP16) and diazaquone/mitoxantrone (AZQ/MITO). Blood 78:460, 1991 (abstr 1829)
18. Stone RM, Berg DT, George SL, et al: Granulocyte-macrophage colony stimulating factor following initial chemotherapy for patients at least 60 years old with primary acute myeloid leukemia: A doubleblinded randomized study. N Engl J Med 332:1671-1677, 1995
19. Moore JO, Schiffer CA, Amrein PC, et al: G-CSF reduces the duration of both granulocytopenia and thrombocytopenia after AZQ/mitoxantrone consolidation in acute myelogenous leukemiaCALGB 9022. Blood 80:291, 1992 (abstr 1156)
20. Koziol JA, Reid N: On multiple comparisons among K samples subject to unequal patterns of censorship. Commun Statist Theor Meth 12:1149-1164, 1977
21. Keating MJ, Smith TL, Kantarjian H, et al: Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome. Leukemia 2:403-412, 1988
22. Schiffer CA, Lee EJ, Tomiyasu T, et al: Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 73:263-270, 1989
23. Bloomfield CD, Lawrence D, Arthur DC, et al: Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 84:111a. 1994 (abstr 431)
24. Bloomfield CD, de la Chapelle A: Chromosome abnormalities in acute nonlymphocytic leukemia: Clinical and biologic significance. Semin Oncol 14:372-383, 1987
25. Arthur DC, Berger R, Golomb HM, et al: The clinical significance of karyolype in acute myelogenous leukemia. Cancer Genet Cytogenet 40:203-216, 1989
26. Sanz GF, Sanz MA, Vallespi M. et al: Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients. Blood 74:395-408, 1989
27. Morel P, Hebbar M, Lai JL, et al: Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 7:1315-1323, 1993
28. Mufti GJ, Stevens JR, Oscier DG, et al: Myelodysplastic syndromes: A scoring system with prognostic significance. Br J Haematol 59:425-433, 1985
29. Seymour JF, Estey EH: The prognostic significance of Auer rods in myelodysplasia. Br J Haematol 85:67-76, 1993
30. Michels SD, Saumur J, Arthur DC, et al: Refractory anemia with excess of blasts in transformation, a hematologic and clinical study of 52 patients. Cancer 64:2340-2346, 1989
31. Fenaux P, Preudhomme C, Estienne MH, et al: De novo myelodysplastic syndromes in adults aged 50 or less. A report on 37 cases. Leuk Res 14:1053-1059, 1990
32. Estey E, Pierce S, Kantarjian H, et al: Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leukemia and Lymphoma 11:59-63, 1989
33. Estey E, Trujillo JM, Cork A, et al: AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes. Hematopathology 6:43-48, 1991
34. Knottenbelt E. Hallett J, Jacobs P: 8; 21 translocation in myelodysplasia secondary to essential thrombocytopenia. Am J Hematol 130:233-235, 1989
35. Czepulkowski B, Gibbons B, Tucker J, et al: Duplication of one of the products of the t(8;21) translocation in a patient with refractory anemia with excess blasts in transformation. Cancer Genet Cytogenet 25:175-177, 1987
36. Gajewski JL, Ho WG, Nimer SD, et al: Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol 7:1637-1645, 1989
37. Hoyle CF, De Bastos M, Wheatley K, et al: AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: Results from the MRC's 9th AML trial. Br J Haematol 72:45-53, 1989
38. Suciu S, Kuse R, Weh HJ, et al: Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome. Cancer Genet Cytogenet 44:15-26, 1990